prikaz prve stranice dokumenta Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?
  Download
PDF 490.9 KB
Scientific paper - Review paper
Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?
Clinical Obesity, (2021), 1; 12439. https://doi.org/10.1111/cob.12439
Belančić, Andrej; Kresović, Andrea; Troskot Dijan, Marija

Linked objects
COVID-19 | Virtual collection
Cite this document

Belančić, A., Kresović, A. & Troskot Dijan, M. (2021). Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?. Clinical Obesity, (1), 6. doi: 10.1111/cob.12439

Belančić, Andrej, et al. "Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?." Clinical Obesity, no. 1, 2021, pp. 6. https://doi.org/10.1111/cob.12439

Belančić, Andrej, Andrea Kresović and Marija Troskot Dijan. "Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?." Clinical Obesity no. 1 (2021): 6. https://doi.org/10.1111/cob.12439

Belančić, A., Kresović, A. and Troskot Dijan, M. (2021) 'Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?', Clinical Obesity, (1), pp. 6. doi: 10.1111/cob.12439

Belančić A, Kresović A, Troskot Dijan M. Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?. Clinical Obesity [Internet]. 2021 January 10 [cited 2024 December 27];(1):6. doi: 10.1111/cob.12439

A. Belančić, A. Kresović and M. Troskot Dijan, "Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?", Clinical Obesity, no. 1, pp. 6, January 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:347912. [Accessed: 27 December 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?
AuthorAndrej Belančić
AuthorAndrea Kresović
AuthorMarija Troskot Dijan
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
The aim of the present manuscript is to discuss on potential pros and cons of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) as glucose‐lowering agents during COVID‐19 pandemic, and what is more to evaluate them as potential candidates for the treatment of patients, affected by COVID‐19 infection, with or even without diabetes mellitus type 2. Besides being important glucose‐lowering agents, GLP‐1RAs pose promising anti‐inflammatory and anti‐obesogenic properties, pulmonary protective effects, as well as beneficial impact on gut microbiome composition. Hence, taking everything previously mentioned into consideration, GLP‐1RAs seem to be potential candidates for the treatment of patients, affected by COVID‐19 infection, with or even without type 2 diabetes mellitus, as well as excellent antidiabetic (glucose‐lowering) agents during COVID‐19 pandemic times.
Keywords (english)
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleClinical Obesity
Numberingno. 1, p. 6, 12439
p-ISSN1758-8103
e-ISSN1758-8111
DOIhttps://doi.org/10.1111/cob.12439
URN:NBNurn:nbn:hr:184:347912
Publication2021-01-10
Document URLhttps://onlinelibrary.wiley.com/doi/10.1111/cob.12439
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) icon
Created on2021-01-19 21:56:50